A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults

Part of paid clinical trials in Grayslake, Illinois.

Sponsor
AbbVie
Study ID
NCT07856706
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy Subjects

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • ABBV-7828 — DRUG
    Oral administration
  • Placebo for ABBV-7828 — DRUG
    Oral administration

Study Details

This study is to evaluate safety, tolerability, pharmacokinetics and effect of food on ABBV-7828 compared to placebo in healthy adult participants.

Key Dates

First listed
Oct 5, 2026
Start date
Sep 21, 2026
Status verified
Sep 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Part 1: ABBV-7828
    Participants will receive single doses of ABBV-7828.
  • Placebo Comparator: Part 1: Placebo
    Participants will receive single doses of placebo.
  • Experimental: Part 2: ABBV-7828 Sequence 1
    Participants will receive ABBV-7828 while in fasting in Period 1 followed by ABBV-7828 after high fat/high calorie meal in Period 2.
  • Experimental: Part 2: ABBV-7828 Sequence 2
    Participants will receive ABBV-7828 after a high-fat/high calorie meal in Period 1 followed by ABBV-7828 in fasting conditions in Period 2.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to approximately 38 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Acpru /Id# 283545GrayslakeIllinois60030-

Find similar trials in Grayslake, IL

By research site

Related Studies